ArticleJournal for immunotherapy of cancer2021

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2

Stanley Ly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.